No. 18-1578

Pfizer Inc. v. Alida Adamyan, et al.

Lower Court: Ninth Circuit
Docketed: 2019-06-25
Status: Denied
Type: Paid
Amici (2) Experienced Counsel
Tags: cafa-removal civil-procedure class-action-fairness-act diversity-jurisdiction federal-court joint-trial mass-action products-liability removal state-court state-court-proposal
Key Terms:
Takings Immigration Jurisdiction ClassAction
Latest Conference: 2019-10-01
Question Presented (AI Summary)

Whether a state court's proposal to try jointly the claims of more than 100 plaintiffs can qualify for 'mass action' removal under the Class Action Fairness Act, 28 U.S.C. § 1332(d)(11)

Question Presented (from Petition)

QUESTION PRESENTED This Petition presents an important, unsettled, and recurring question concerning the “mass action” provisions of the Class Action Fairness Act (CAFA). Under CAFA, a removable “mass action” is a minimally diverse civil action in which the monetary claims of 100 or more persons are “proposed to be tried jointly on the ground that the plaintiffs’ claims involve common questions of law or fact.” 28 U.S.C. § 1332(d)(11). The courts of appeals are divided as to whether a swa sponte proposal by a state court—as opposed to a proposal by plaintiffs—can trigger mass action removal. Here, Pfizer removed these cases involving more than 4,200 products liability plaintiffs following a California state court’s “Request” to coordinate them all before a single trial judge. But the district court remanded the litigation to state court based on its view that a state court’s proposal for joint trial cannot trigger removal under CAFA, and the Ninth Circuit declined to correct the district court’s misreading of the statute. The question presented is whether a state court’s proposal to try jointly the claims of more than 100 plaintiffs can qualify for “mass action” removal under the Class Action Fairness Act, 28 U.S.C. § 1332(d)(11).

Docket Entries

2019-10-07
Petition DENIED.
2019-09-11
DISTRIBUTED for Conference of 10/1/2019.
2019-09-10
Reply of petitioner Pfizer, Inc. filed.
2019-08-26
Brief of respondents Alida Adamyan, et al. in opposition filed.
2019-07-25
Brief amici curiae of American Tort Reform Association, et al. filed.
2019-07-25
Brief amicus curiae of Washington Legal Foundation filed.
2019-07-15
Motion to extend the time to file a response is granted and the time is extended to and including August 26, 2019.
2019-07-09
Motion to extend the time to file a response from July 25, 2019 to August 24, 2019, submitted to The Clerk.
2019-06-21
Petition for a writ of certiorari filed. (Response due July 25, 2019)
2019-03-28
Application (18A980) granted by Justice Kagan extending the time to file until June 21, 2019.
2019-03-25
Application (18A980) to extend the time to file a petition for a writ of certiorari from April 22, 2019 to June 21, 2019, submitted to Justice Kagan.

Attorneys

Alida Adamyan, et al.
Jules Burton LeBlanc IVBaron & Budd, P.C., Respondent
Jules Burton LeBlanc IVBaron & Budd, P.C., Respondent
Bill Robins IIIRobins Cloud, Respondent
Bill Robins IIIRobins Cloud, Respondent
American Tort Reform Association, et al.
John H. BeisnerSkadden, Arps, Slate, Meagher & Flom LLP, Amicus
John H. BeisnerSkadden, Arps, Slate, Meagher & Flom LLP, Amicus
Pfizer, Inc.
Michael Hugh McGinleyDechert LLP, Petitioner
Michael Hugh McGinleyDechert LLP, Petitioner
Washington Legal Foundation
Richard A. SampWashington Legal Foundation, Amicus
Richard A. SampWashington Legal Foundation, Amicus